⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BLRX News
BioLineRX Ltd
BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types
prnewswire.com
BLRX
BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers
prnewswire.com
BLRX
BLRX